KOD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kodiak Sciences Inc (KOD) is not a strong buy for a beginner, long-term investor at this moment. While the stock has bullish technical indicators and positive analyst sentiment, insider selling, lack of recent news catalysts, and weak financial performance weigh against it. The absence of Intellectia Proprietary Trading Signals further reduces the urgency to act now. It is better to monitor the stock for stronger entry signals or improved fundamentals.
The technical indicators for KOD are bullish. The MACD histogram is positive at 1.301, showing upward momentum, and the RSI_6 at 70.791 is neutral. Moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 44.227), with support at S1: 34.868.
based on strong Phase 3 trial results for tarcocimab and KSI-501, which show improved safety and efficacy. Accelerated Biologics License Application timing is another positive development.
Insider selling has surged by 45259.39% in the last month, indicating potential lack of confidence from company insiders. Additionally, there is no recent news or Congress trading activity to act as a positive catalyst. Financials remain weak, with no revenue and a net loss of $56.7M in Q4 2025.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $56.7M, though net income improved by 28.64% YoY. EPS also improved to -1.04 (up 23.81% YoY), but overall financial performance remains weak with no gross margin.
Analysts are bullish on KOD, with multiple firms raising price targets significantly (UBS: $80, H.C. Wainwright: $58, Jefferies: $56) and maintaining Buy ratings. Positive trial results and accelerated regulatory timelines are key drivers of optimism.
